SSG
BMY icon

Summit Securities Group’s Bristol-Myers Squibb BMY Stock Holding History

Summit Securities Group’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,100
Closed -$79K – 842
2022
Q4 		$79K Hold
1,100
– – ﹤0.01% 638
2022
Q3 		$78K Sell
1,100
-35,900
-97% -$2.6M 0.01% 560
2022
Q2 		$2.85M Sell
37,000
-25,500
-41% -$1.94M 0.35% 52
2022
Q1 		$4.56M Buy
62,500
+45,000
+257% +$3.02M 0.51% 38
2021
Q4 		$1.09M Buy
17,500
+17,321
+9,677% +$1.02M 0.05% 235
2021
Q3 		$1.06M Sell
179
-91
-34% -$5.99K 0.08% 251
2021
Q2 		$1.8M Buy
270
+169
+167% +$11K 0.15% 149
2021
Q1 		$638K Sell
101
-3,028
-97% -$188K 0.07% 275
2020
Q4 		$19.4M Buy
3,129
+136
+5% +$8.36K 1.63% 4
2020
Q3 		$18M Sell
2,993
-145
-5% -$8.73K 1.89% 8
2020
Q2 		$18.5M Sell
3,138
-758
-19% -$45.3K 2.29% 7
2020
Q1 		$21.7M Sell
3,896
-2,513
-39% -$154K 3.82% 2
2019
Q4 		$41.1M Buy
6,409
+3,869
+152% +$222K 3.11% 4
2019
Q3 		$12.9M Sell
2,540
-1,050
-29% -$49.3K 1.14% 12
2019
Q2 		$16.3M Buy
3,590
+802
+29% +$37.4K 1.89% 10
2019
Q1 		$13.3M Buy
2,788
+2,746
+6,538% +$137K 2.43% 9
2018
Q4 		$218K Buy
+42
New +$2.26K 0.02% 281
2017
Q1 		– Sell
-41
Closed -$240K – 301
2016
Q4 		$240K Sell
41
-209
-84% -$11.4K 0.05% 230
2016
Q3 		$1.35M Buy
+250
New +$16.1K 0.45% 39
2016
Q1 		– Sell
-76
Closed -$2K – 160
2015
Q4 		$2K Buy
+76
New +$5.02K ﹤0.01% 255
2015
Q1 		– Sell
-448
Closed -$7K – 403
2014
Q4 		$7K Buy
448
+256
+133% +$14.4K ﹤0.01% 475
2014
Q3 		$9K Buy
+192
New +$9.59K ﹤0.01% 541
2014
Q1 		– Sell
-827
Closed -$4K – 415
2013
Q4 		$4K Buy
827
+393
+91% +$20K ﹤0.01% 402
2013
Q3 		$5K Buy
434
+262
+152% +$11.5K ﹤0.01% 297
2013
Q2 		$2K Buy
+172
New +$7.47K ﹤0.01% 474

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Summit Securities Group's BMY Position: Q1 2026 in Review

Summit Securities Group reduced its Bristol-Myers Squibb (BMY) stake by 96% in Q1 2026, selling an estimated $4.8M and leaving 3,134 shares worth $190K. The position accounts for 0.02% of the portfolio, ranked #231.

Summit Securities Group first reported a position in BMY in Q2 2013 and has held it in 45 quarters since. The position peaked at $22.6M in Q4 2019. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Summit Securities Group held 3,134 shares of Bristol-Myers Squibb worth $190K as of Q1 2026.
  • Summit Securities Group sold 82,290 Bristol-Myers Squibb shares in Q1 2026, an estimated $4.8M.
  • Bristol-Myers Squibb made up 0.02% of Summit Securities Group's portfolio in Q1 2026, its #231 holding.
  • Summit Securities Group first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 45 quarters since.
  • Summit Securities Group's Bristol-Myers Squibb position peaked at $22.6M in Q4 2019.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.